Aura Biosciences, Inc. Common Stock
AURAAura Biosciences, Inc. is a biotechnology company focused on developing targeted therapies for eye diseases, particularly focusing on ophthalmic oncology. The company specializes in utilizing optical coherence tomography (OCT)-guided photodynamic therapy to treat ocular conditions, including choroidal melanoma. Aura Biosciences aims to improve treatment outcomes while minimizing damage to healthy tissues.
Company News
Aura Biosciences, a clinical-stage biotechnology company, will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, discussing their precision therapies for solid tumors.
Aura Biosciences reported Q2 2025 financial results, highlighting continued clinical development of bel-sar for ocular and bladder cancers, raising $75 million in equity, and maintaining a cash runway into early 2027.
Aura Biosciences reported Q2 2025 financial results, highlighting ongoing clinical trials for bel-sar in early choroidal melanoma and non-muscle invasive bladder cancer. The company raised $75 million in equity financing and expects cash to fund operations into the first half of 2027.
Aura Biosciences announced the pricing of a public offering of common stock and warrants, raising $75 million. The company plans to use the proceeds to advance its clinical programs in various cancer indications.
Aura Biosciences, a clinical-stage biotechnology company, announced the appointment of Teresa Bitetti, President of the Global Oncology Business Unit at Takeda, to its Board of Directors. Bitetti's extensive operational and commercial experience will be valuable as Aura advances its clinical pipeline in ocular and urologic oncology.
